



## **Christopher Gibson, PhD**

**Distinguished Scientist**

**Merck**

*ADME Sciences: Where are we now and where do we go next?"*

Dr. Gibson graduated in 1996 with a B.S. degree in biochemistry from The Ohio State University in Columbus, Ohio. In 2001 he obtained a Doctoral degree from the Department of Pharmaceutics in the School of Pharmacy at The Ohio State University in Columbus, Ohio. Since joining Merck in September 2001 he has directly provided and led groups providing laboratory and project representation ADME support to small and large molecule discovery and development programs spanning a wide range of therapeutic indications. Additionally, Dr. Gibson has led a network of scientists to evaluate the current state of human pharmacokinetic predictions and to develop innovative technologies and models to improve human pharmacokinetic and drug-drug interaction predictions within Merck. He is currently a Distinguished Scientist within the department of Pharmacokinetics, Dynamics, Metabolism and Bioanalytical (PDMB) in Merck Research Laboratories providing direct and strategic pipeline support and contributing to shaping future departmental scientific and program strategy. Recently Dr. Gibson was named co-Chair for the Translational ADME Sciences Leadership Group (TALG) within the IQ-Consortium, a non-profit providing opportunities for biopharmaceutical companies to work pre-competitively on current scientific challenges in drug discovery and development. Dr. Gibson currently has 38 publications in the fields of drug metabolism, drug-drug interactions, pharmacokinetics (including PBPK) and PKPD modeling and prediction of human dose.